The current study examined the evolving pneumococcal landscape to provide updated baseline data for childhood immunization policies. Following extensive PCV13 use, vaccine-targeted serotypes had ...
The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the ...
(RTTNews) - Merck & Co. Inc. (MRK) announced that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE ® ...
In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
With an expanded usage recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines from Pfizer and Merck are poised to add millions more eligible ...
Pneumococcal community-acquired pneumonia (CAP) was a significant cause of hospitalizations in US adults, especially among those aged 65 years or older. This was largely due to Streptococcus ...
The Australian government announced last week there's a new vaccine for pneumococcal disease on the National Immunization Program for all children. This vaccine replaces previously listed pneumococcal ...
Add Yahoo as a preferred source to see more of our stories on Google. Less than half (44%) of eligible respondents said they planned to get a pneumococcal vaccine; fewer than one in four (24%) said ...
National-level CDC surveillance data shows CAPVAXIVE covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases, compared to approximately 52% covered by PCV20 ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...